Share on StockTwits

AstraZeneca plc (ADR) (NYSE:AZN)‘s stock had its “hold” rating restated by equities research analysts at Deutsche Bank in a research note issued to investors on Monday, Analyst Ratings.Net reports.

AZN has been the subject of a number of other recent research reports. Analysts at Societe Generale reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Wednesday, May 7th. Separately, analysts at Beaufort Securities downgraded shares of AstraZeneca plc (ADR) to a “hold” rating in a research note on Wednesday, May 7th. Finally, analysts at Danske downgraded shares of AstraZeneca plc (ADR) from a “buy” rating to a “sell” rating in a research note on Monday, May 5th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $68.00.

AstraZeneca plc (NYSE:AZN) traded up 0.82% during mid-day trading on Monday, hitting $77.87. The stock had a trading volume of 2,914,849 shares. AstraZeneca plc has a 1-year low of $46.87 and a 1-year high of $82.68. The stock’s 50-day moving average is $68.94 and its 200-day moving average is $62.39. The company has a market cap of $98.194 billion and a price-to-earnings ratio of 47.36.

AstraZeneca plc (ADR) (NYSE:AZN) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.17 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.